Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models

Matthew D. Thompson, Clinton J. Grubbs, Ann M. Bode, Joel M. Reid, Renee McGovern, Philip S. Bernard, Inge J. Stijleman, Jeffrey E. Green, Christina Bennett, M. Margaret Juliana, Fariba Moeinpour, Vernon E. Steele, Ronald A. Lubet

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Epidemiologic studies have shown that diabetics receiving the biguanide metformin, as compared with sulfonylureas or insulin, have a lower incidence of breast cancer. Metformin increases levels of activated AMPK (AMP-activated protein kinase) and decreases circulating IGF-1; encouraging its potential use in both cancer prevention and therapeutic settings. In anticipation of clinical trials in nondiabetic women, the efficacy of metformin in nondiabetic rat and mouse mammary cancer models was evaluated. Metformin was administered by gavage or in the diet, at a human equivalent dose, in standard mammary cancer models: (i) methylnitrosourea (MNU)-induced estrogen receptor-positive (ER +) mammary cancers in rats, and (ii) MMTV-Neu/p53KO ER- (estrogen receptor - negative) mammary cancers in mice. In the MNU rat model, metformin dosing (150 or 50 mg/kg BW/d, by gavage) was ineffective in decreasing mammary cancer multiplicity, latency, or weight. Pharmacokinetic studies of metformin (150 mg/kg BW/d, by gavage) yielded plasma levels (Cmax and AUC) higher than humans taking 1.5 g/d. In rats bearing small palpable mammary cancers, short-term metformin (150 mg/kg BW/d) treatment increased levels of phospho-AMPK and phospho-p53 (Ser20), but failed to reduce Ki67 labeling or expression of proliferation-related genes. In the mouse model, dietary metformin (1,500 mg/kg diet) did not alter final cancer incidence, multiplicity, or weight. Metformin did not prevent mammary carcinogenesis in two mammary cancer models, raising questions about metformin efficacy in breast cancer in nondiabetic populations.

Original languageEnglish (US)
Pages (from-to)231-239
Number of pages9
JournalCancer Prevention Research
Volume8
Issue number3
DOIs
StatePublished - Mar 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models'. Together they form a unique fingerprint.

  • Cite this

    Thompson, M. D., Grubbs, C. J., Bode, A. M., Reid, J. M., McGovern, R., Bernard, P. S., Stijleman, I. J., Green, J. E., Bennett, C., Juliana, M. M., Moeinpour, F., Steele, V. E., & Lubet, R. A. (2015). Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. Cancer Prevention Research, 8(3), 231-239. https://doi.org/10.1158/1940-6207.CAPR-14-0181-T